NASDAQ:UBXUnity Biotechnology Stock Price, Forecast & News

$8.74

0.00 (0.00 %)

(As of 06/4/2020 04:00 PM ET)

Add

Compare

Today's Range

$8.53

Now: $8.74▼

$9.10

50-Day Range

$6.16

MA: $6.99▼

$9.38

52-Week Range

$4.62

Now: $8.74▼

$10.38

Volume277,157 shs

Average Volume225,445 shs

Market Capitalization$429.51 million

P/E RatioN/A

Dividend YieldN/A

Beta0.36

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 that is in Phase 1 clinical study for musculoskeletal disease; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was founded in 2009 and is headquartered in Brisbane, California.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
Unity Biotechnology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $22.00, Unity Biotechnology has a potential upside of 151.7% from its current price of $8.74.
Amount of Analyst Coverage
Unity Biotechnology has only been the subject of 1 research reports in the past 90 days.

2.5 Community Rank

Outperform Votes
Unity Biotechnology has received 121 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Unity Biotechnology has received 122 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Unity Biotechnology has received 50.21% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Unity Biotechnology and other stocks. Vote “Outperform” if you believe UBX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe UBX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Unity Biotechnology does not currently pay a dividend.
Dividend Growth
Unity Biotechnology does not have a long track record of dividend growth.

2.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Unity Biotechnology insiders have not sold or bought any company stock.
Percentage Held by Insiders
37.30% of the stock of Unity Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
44.56% of the stock of Unity Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Unity Biotechnology are expected to grow in the coming year, from ($1.92) to ($1.62) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Unity Biotechnology is -4.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Unity Biotechnology is -4.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Overall Beat the Market Rank^™

1.73 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry N/A

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:UBX

Previous Symbol

CUSIPN/A

CIK1463361

WebN/A

PhoneN/A

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Employees94

Outstanding Shares49,143,000

Market Cap$429.51 million

Next Earnings Date8/5/2020 (Estimated)

OptionableNot Optionable

Receive UBX News and Ratings via Email

Sign-up to receive the latest news and ratings for UBX and its competitors with MarketBeat's FREE daily newsletter.

Unity Biotechnology (NASDAQ:UBX) Frequently Asked Questions

How has Unity Biotechnology's stock been impacted by COVID-19 (Coronavirus)?

Unity Biotechnology's stock was trading at $5.39 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, UBX stock has increased by 62.2% and is now trading at $8.74. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Unity Biotechnology?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unity Biotechnology in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Unity Biotechnology.

When is Unity Biotechnology's next earnings date?

Unity Biotechnology is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Unity Biotechnology.

How were Unity Biotechnology's earnings last quarter?

Unity Biotechnology Inc (NASDAQ:UBX) issued its earnings results on Thursday, May, 7th. The company reported ($0.54) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.51) by $0.03. View Unity Biotechnology's earnings history.

What price target have analysts set for UBX?

3 analysts have issued 1 year price targets for Unity Biotechnology's shares. Their forecasts range from $13.00 to $33.00. On average, they anticipate Unity Biotechnology's share price to reach $22.00 in the next twelve months. This suggests a possible upside of 151.7% from the stock's current price. View analysts' price targets for Unity Biotechnology.

Has Unity Biotechnology been receiving favorable news coverage?

Media coverage about UBX stock has trended somewhat positive this week, according to InfoTrie. The research firm rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Unity Biotechnology earned a media sentiment score of 0.7 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutUnity Biotechnology.

Who are some of Unity Biotechnology's key competitors?

Some companies that are related to Unity Biotechnology include Passage Bio (ZNTL), Glaukos (GKOS), Mesoblast (MSB), ProShares UltraShort DJ-UBS Commodity (CMD), Zymeworks (ZYME), Xencor (XNCR), SpringWorks Therapeutics (SWTX), USANA Health Sciences (USNA), Epizyme (EPZM), Aurinia Pharmaceuticals (AUPH), Immunovant (IMVT), Madrigal Pharmaceuticals (MDGL), Heron Therapeutics (HRTX), Adverum Biotechnologies (ADVM) and Theravance Biopharma (TBPH). View all competitors.

What other stocks do shareholders of Unity Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Unity Biotechnology investors own include Canopy Growth (CGC), NIO (NIO), Gilead Sciences (GILD), NVIDIA (NVDA), AbbVie (ABBV), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), JD.Com (JD), Sorrento Therapeutics (SRNE) and Advanced Micro Devices (AMD).

Who are Unity Biotechnology's key executives?

Unity Biotechnology's management team includes the following people:

Dr. Nathaniel E. David, Co-Founder, Pres & Exec. Director (Age 52, Pay $640.86k)
Mr. Robert C. Goeltz II, Chief Financial Officer (Age 47, Pay $577.3k)
Dr. Anirvan Ghosh, Director & CEO (Age 56)
Dr. Jan M. van Deursen, Founder
Dr. Judith Campisi, Founder

When did Unity Biotechnology IPO?

(UBX) raised $85 million in an initial public offering (IPO) on Thursday, May 3rd 2018. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup served as the underwriters for the IPO and Mizuho Securities was co-manager.

What is Unity Biotechnology's stock symbol?

Unity Biotechnology trades on the NASDAQ under the ticker symbol "UBX."

Who are Unity Biotechnology's major shareholders?

Unity Biotechnology's stock is owned by many different retail and institutional investors. Top institutional investors include State Street Corp (0.95%), Geode Capital Management LLC (0.82%), Russell Investments Group Ltd. (0.45%), Nuveen Asset Management LLC (0.22%), Bank of New York Mellon Corp (0.16%) and Morgan Stanley (0.12%).

Which major investors are selling Unity Biotechnology stock?

UBX stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Moloney Securities Asset Management LLC, State Street Corp, UBS Group AG, Squarepoint Ops LLC, Virtus ETF Advisers LLC, and JPMorgan Chase & Co..

Which major investors are buying Unity Biotechnology stock?

UBX stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Geode Capital Management LLC, Investors Financial Group LLC, Verity Asset Management Inc., Nuveen Asset Management LLC, Alliancebernstein L.P., BNP Paribas Arbitrage SA, and Cit Bank NA Wealth Management.

How do I buy shares of Unity Biotechnology?

Shares of UBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Unity Biotechnology's stock price today?

One share of UBX stock can currently be purchased for approximately $8.74.

How big of a company is Unity Biotechnology?

Unity Biotechnology has a market capitalization of $429.51 million. Unity Biotechnology employs 94 workers across the globe.

This page was last updated on 6/4/2020 by MarketBeat.com Staff